X

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Nexvax2 in Patients With Celiac Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 19 May 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HLA DQ2 peptide vaccine (Primary)
Indications Coeliac disease
Focus Adverse reactions
Sponsors ImmusanT

Most Recent Events

12 May 2017 Results from this and other trial (see profile 239677) published in an ImmusanT Media Release
11 May 2017 Results from this and other trial (see profile 239677) published in The Lancet Gastroenterology and Hepatology
22 Mar 2017 Status changed to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com